A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss drug Zepbound in the U.S.

(Reuters) -Telehealth firms Teladoc and LifeMD said on Thursday they had signed an agreement with Gifthealth, the pharmacy partner of Eli Lilly's direct-to-consumer site, LillyDirect, to offer patients the weight-loss drug,

Morgan Stanley noted that two compounding groups – the Outsourcing Facilities Association and North American Custom Laboratories – filed a

Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 construction workers.

Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional $27 billion to build four new manufacturing plants in the United States, shoring up domestic manufacturing as President Donald Trump threatens new tariffs on pharmaceuticals.

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

Eli Lilly has launched new 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide), priced at $499 per month under the newly introduced Zepbound Self

Eli Lilly said it plans to build three new plants in the United States to make the key ingredients used in pharmaceuticals, part of a doubling of its investment in manufacturing.

The pharmaceutical company expects the expansion will create thousands of jobs.

Telehealth firms Teladoc Health and LifeMD said on Thursday they have signed an agreement with Eli Lilly's direct-to-consumer website LillyDirect pharmacy partner, Gifthealth, to offer patients the weight-loss drug,